R&D Centre

In 2023, Evolet Healthcare commenced the construction of its advanced R&D center, equipped with world-class formulation units to meet regulatory standards in various markets including Europe, CIS, Australia, SEAS, and Latin America. The center will specialize in harmonized dossier development for regulatory approval.

 

THE FACILITY’S FORMULATION DEVELOPMENT CAPACITY WILL INCLUDE:

 

  • Oral Solids:

     

    Various tablet forms (uncoated, film coated, sustained release, extended release, bilayered) and capsules (immediate and controlled release).

     

  • Sterile Formulation:

     

    Vials (lyophilized and non-lyophilized injections) and ampoules, ophthalmic preparations.

     

  • Liquid Formulation:

     

    Including suspensions, solutions, emulsions, powder for suspensions, and liquid stick packs.

     

  • Semisolid Formulation:

     

    Such as creams, ointments, lotions, and suppositories. This expansion signifies Evolet Healthcare’s commitment to cutting-edge research and development in pharmaceutical formulations.

     

 

City